Systemic sclerosis & Raynaud's
Role of intravenous immunoglobulins in systemic sclerosis (SSc): A systematic literature review
Authors' conclusion
IVIG showed benefit in treating some manifestations of SSc, however there was a lack of convincing evidence for the efficacy in others.
Study context
- Population
- Adults with SSc (≥5 per study) receiving Intravenous Immunoglobulin (IVIG); English-language full texts, 01/01/2003–15/04/2024
- Participants
- 266 adults12 studies
- Outcome
- Role of IVIG across SSc manifestations
Main finding
As reported in the abstract
- Favourable effect of IVIG in reducing extent of skin thickening, muscle and joint pain, gastrointestinal symptoms, steroid dosing and improving patient/physician reported quality of life
- IVIG may appear less beneficial for respiratory disease; stabilisation in pulmonary function tests and radiological features may be considered a positive outcome
- 18 outcomes across five organ systems
- 1 RCT, 2 pilot, 1 open label, 7 retrospective, 1 case control study
- Lack of high-quality studies; concomitant therapies in many studies
Original publication
Role of intravenous immunoglobulins in systemic sclerosis (SSc): A systematic literature review. Semin Arthritis Rheum. Published 22 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →